iliadbio.comContact us
About company
ILiAD Biotechnologies (ILiAD) is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. ILiAD's lead candidate is BPZE1, a live-attenuated pertussis vaccine that has successfully completed a Phase 1 human clinical trial. ILiAD Biotechnologies is a registered Delaware company founded in 2012.
Unknown
Unknown
Not verified company
